Keros Therapeutics Inc - KROS Net earnings per one share for the last twelve months

Keros Therapeutics Inc (KROS) - corporate logo

High barriers to entry in the hematology sector and patent protection shield Keros Therapeutics (KROS) from competition. The rolling annual growth rate of net income per share demonstrates a sustainable trend, where the value -278.30 captures the metric level. Scaling relies on a future monopoly upon drug approval, despite current R&D losses. The company's stability is ensured by the recruitment of leading translational medicine specialists.

KROS: kerostx.com Net earnings per share for the last 12 months 02/11/2024 - 11/18/2026

Keros Therapeutics - analytical breakdowns and key metrics (KROS)

Fundamental company valuation:KROS - Keros Therapeutics Inc
Brand item of Keros Corp

Keros Therapeutics (KROS) is establishing cutting-edge standards for treating hematological pathologies by creating a unique protein regulation ecosystem. By analyzing the annual EPS TTM growth rate, investors can assess net income dynamics over the last four quarters, which helps determine the business model's resilience to market volatility and prevents impulsive decisions when evaluating the fundamental value of this biotech asset.

Competitor analysis

Earnings per one share for the last 12 months VRTX|ALNY: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Insmed Inc (INSM)|UTHR (United Therapeutics Corporation) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months BMRN (BioMarin)|Net earnings per share for the last 12 months BBIO (BridgeBio)|BGM: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Cogent Biosciences, Inc. COGT|XERS (Xeris Biopharma Inc) - Earnings per one share for the last 12 months|Arcturus Therapeutics - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ETON (Eton Pharmaceuticals)|KMDA: Net earnings per share (EPS TTM)|Fulcrum Therapeutics Inc (FULC) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months abeonatherapeutics.com|MREO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) PLX|Net earnings per share for the last 12 months Pliant Therapeutics, Inc. PLRX|Net earnings per share (EPS TTM) APLT (Applied Therapeutics Inc.)|Net earnings per share (EPS TTM) Rein Therapeutics Inc. RNTX|gelteq.com - Net earnings per share (EPS TTM)|AYTU - Net earnings per share (EPS TTM)|CMMB: Net earnings per share (EPS TTM)|SRx Health Solutions Inc. - Earnings per share for the trailing year|Earnings per share for the last twelve months Polyrizon Ltd|AEZS (Aeterna Zentaris) - Earnings per share for the last four quarters|Earnings per share for the last twelve months CTD Holdings (CYTH)|INZY: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Reneo Pharmaceuticals Inc. RPHM|Net earnings per share for the last four quarters COSCIENS Biopharma Inc. (CSCI)